GLP-1s May Ease Symptom Burden in Patients With Fibromyalgia
The use of GLP-1 receptor agonists was linked to lower pain and fatigue in patients with fibromyalgia, according to a large-scale health records analysis.
METHODOLOGY:
Researchers used the TriNetX database to identify patients with a diagnosis of fibromyalgia, with or without documented use of GLP-1s.
Used propensity score matching to form two patient cohorts (GLP-1 users vs nonusers), each consisting of 38,439 patients.
Assessed for documented opioid use and International Classification of Diseases, 10th Revision (ICD-10) codes for chronic pain, fatigue, and malaise.
Followed patients for 5 years, starting 1 year after their fibromyalgia diagnosis and initiation of GLP-1 medication.
TAKEAWAY:
Patients with fibromyalgia who were taking GLP-1s were less likely to use opioids than the comparison group (47.3% vs 59.9%).
The GLP-1 group also had lower rates of reported fatigue, malaise, and pain.
Ongoing fibromyalgia care (defined by the presence of the ICD-10 code for fibromyalgia) was lower in the GLP-1 group (39.1%) than in the nonuser group (55.7%).
Additional research is needed using validated outcome measures like the Fibromyalgia Impact Questionnaire and Patient-Reported Outcomes Measurement Information System.
IN PRACTICE:
'The way that I use it in my practice these days is that if I have a patient with chronic pain or with fibromyalgia who has comorbidities that already have an FDA approval for GLP-1 use, such as obesity, diabetes, or obstructive sleep apnea, I would encourage them to go to their primary care physician and maybe consider getting started on a GLP-1,' said presenter Nouran Eshak, MB ChB, of the Mayo Clinic in Scottsdale, Arizona.
SOURCE:
This abstract was presented at the European Alliance of Associations for Rheumatology (EULAR) 2025 Annual Meeting in Barcelona, Spain.
LIMITATIONS:
This study had a retrospective design and relied on ICD-10 coding. Validated fibromyalgia-specific symptom scales or outcome measures were not available. Researchers were unable to account for confounders such as duration of illness, symptom severity, GLP-1 dosage, or access to healthcare.
DISCLOSURES:
The study authors disclosed having no relevant financial relationships.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Man suffers spinal injuries after jumping off boat near North Shore beach
A young man was flown to the hospital with spinal injuries after police say he jumped off a boat and struck his head near a beach on the North Shore of Massachusetts on Friday. Emergency crews responding to a report of a person who dove off a boat, struck his head, and suffered a serious injury off Crane Estate in Ipswich just after 5 p.m. learned that a man in his 20s was undergoing life-saving care on Steep Hill Beach, Ipswich Police Chief Paul Nikas and Ipswich Fire Chief Paul Parisi said in a joint news release. When crews arrived at the beach, they learned that he had suffered acute spinal injuries and called for a Boston MedFlight helicopter, according to Nikas and Parisi. The helicopter landed on the beach, where firefighters and EMS personnel treated the conscious man, who was then flown to Lahey Hospital and Medical Center in Burlington for additional care. Parisi credited Crane Beach personnel with pulling the man from the water and performing life-saving measures that 'likely averted a fatality.' The incident remains under investigation. Download the FREE Boston 25 News app for breaking news alerts. Follow Boston 25 News on Facebook and Twitter. | Watch Boston 25 News NOW Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
BioNTech SE and Pfizer recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's focus on innovation and strategic partnerships like the one with XtalPi possibly countered broader market moves, which saw a smaller 1% increase in the same period. We've identified 3 warning signs for Pfizer that you should be aware of. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent positive recommendation from the European Medicines Agency for the COVID-19 vaccine developed by BioNTech SE and Pfizer has contributed to an 8% increase in Pfizer's share price over the last quarter. This news may provide a temporary boost to Pfizer's revenue and earnings forecasts, especially as the company continues to innovate amidst legal challenges and declining earnings. The authorization could enhance immediate market confidence in Pfizer's product pipeline, impacting future revenue projections positively. Over the past year, Pfizer experienced a total return of 13.78% including dividends, reflecting a challenging period for shareholders. When compared to the broader US market's return of 17.2% over the same period, Pfizer has underperformed, highlighting investor concerns over competitive pressures and revenue growth prospects. The current share price movement toward the analyst consensus price target of $29.23 suggests a cautiously optimistic outlook among some market participants. Analysts' revenue forecasts reflect potential declines due to increased competition for existing products, yet others anticipate that strategic shifts in research focus, especially in oncology, might mitigate future earnings risks. With a modest increase of 8% in shares largely tied to vaccine authorization, it underscores the uncertainty surrounding longer-term performance relative to bearish analyst expectations. Understand Pfizer's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Washington Post
an hour ago
- Washington Post
Company involved in Coldplay KissCam drama hires Gwyneth Paltrow as spokesperson
BOSTON — Astronomer — the company whose CEO resigned after being caught on a KissCam at a Coldplay rock concert embracing a woman who was not his wife — is trying to move on from the drama with someone who knows the band pretty well. Actress Gwyneth Paltrow, who was married to Coldplay's frontman Chris Martin for 13 years, announced Friday on X that she has been hired by Astronomer as a spokesperson. Astronomer, a tech company based in New York, found itself in an uncomfortable spotlight when two of its executives were caught on camera in an intimate embrace at a Coldplay concert — a moment that was then flashed on a giant screen in the stadium. CEO Andy Byron and human resource executive Kristin Cabot were caught by surprise when Martin asked the cameras to scan the crowd during a concert earlier this month. 'Either they're having an affair or they're just very shy,' Martin joked when the couple appeared on screen and quickly tried to hide their faces. In a short video, the 'Shakespeare in Love' and 'Ironman' star said she had been hired as a 'very temporary' spokesperson for Astronomer. 'Astronomer has gotten a lot of questions over the last few days and they wanted me to answer the most common ones,' Paltrow said, smiling and deftly avoiding mention of the KissCam fuss. 'We've been thrilled that so many people have a newfound interest in data workflow automation,' she said. 'We will now be returning to what we do best — delivering game-changing results for our customers.' When footage from the KissCam first spread online, it wasn't immediately clear who the couple were. Soon after the company identified the pair, and Byron resigned followed by Cabot. The video clip resulted in a steady stream of memes, parody videos and screenshots of the pair's shocked faces filling social media feeds. Online streams of Coldplay's songs jumped 20% in the days after the video went viral, according to Luminate, an industry data and analytics company.
